Compare iShares MSCI South Korea ETF (EWY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares MSCI South Korea ETF trades at $178.05 (market cap $26.25B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.9× iShares MSCI South Korea ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares MSCI South Korea ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 46 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| EWY | REGN | |
|---|---|---|
Market Cap | $26.25B | $76.14B |
Volume | 19,056,075 | 500,239 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $852.03 |
52-Week Low | $80.72 | $557.73 |
Typical Hold Time | 46 Days | 107 Days |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, trades at $183.72, down 1.44% amid mixed technical signals and KOSPI volatility driven by semiconductor sector sensitivity. The ETF shows neutral momentum with bullish moving averages but faces resistance near $185. Recent news highlights South Korea's strong 2026 market performance and AI-driven semiconductor demand, though concerns persist about high oil prices and rising US yields impacting tech valuations.
Outlook remains cautiously optimistic given EWY's heavy concentration in Samsung and SK hynix, which benefit from AI memory cycle strength. Key risks include reliance on two stocks, geopolitical tensions, and macroeconomic pressures. The ETF offers exposure to South Korea's tech-led growth but requires monitoring of memory cycle trends and foreign investor flows.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
